Background Radiotherapy (RT) plays an integral role in the combined-modality
management of cervical cancer. Various molecular mechanisms have been implicated in the …

Background: Chemo-resistance is one of the key causal factors in cancer death and
emerging evidences suggest that microRNAs (miRNAs) have critical roles in the regulation …

Enhanced chemoresistance is, among other factors, believed to be responsible for treatment
failure and tumor relapse in patients with epithelial ovarian cancer (EOC). Here, we exposed …

Combined chemotherapeutic treatment is the method of choice for advanced and metastatic
gastric tumors. However, resistance to chemotherapeutic agents is one of the main …

Cisplatin spearheads the anticancer chemotherapeutics in present-day use although acute
toxicity is its primary impediment factor. Among a plethora of experimental medications, a …

Ovarian cancer is the most aggressive gynecological cancer. One reason for the low 5-year
survival rate of under 40% is that ovarian tumors usually acquire resistance to the platinum …

Cisplatin (CDDP) is the drug of choice against different types of cancer. However, tumor
cells can acquire resistance to the damage caused by cisplatin, generating genetic and …

The identification of agents that can reverse drug resistance in cancer chemotherapy, and
enhance the overall efficacy is of great interest. Paclitaxel (PTX) belongs to taxane family …

Cervical cancer (CC) is a major gynecological problem in developing and underdeveloped
countries. Despite the significant advancement in early detection and treatment modalities …

Acquisition of epithelial‐mesenchymal transition (EMT) has recently been proposed as an
important contributor of drug resistance in cervical cancer cells. However, the underlying …